Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01256398
Show Display Options
Rank Status Study
1 Active, not recruiting Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Untreated Adult Acute Lymphoblastic Leukemia
Interventions: Biological: Alemtuzumab;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Procedure: In Vitro-Treated Peripheral Blood Stem Cell Transplantation;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Biological: Pegfilgrastim;   Drug: Methotrexate;   Drug: Leucovorin Calcium;   Drug: Melphalan;   Drug: Tacrolimus;   Drug: Etoposide Phosphate;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Vincristine Sulfate;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years